Recent filings with the Securities and Exchange Commission detail significant stock transactions involving Ye Weiguo, Chief Operating Officer at GYRE THERAPEUTICS, INC. (NASDAQ:GYRE). According to a review of SEC Form 4 filings made on May 20 and May 21, 2026, Mr. Ye reported the sale of common stock totaling $136,653.
On May 20th, Mr. Ye executed transactions resulting in the disposal of 9,400 shares of the company's common stock. The weighted average price for these sales was established at $6.15 per share. These specific units were sold through multiple separate transactions, with individual sale prices recorded ranging between $6.0908 and $6.2935.
The following day, May 21st, saw the disposal of an additional 12,820 shares of common stock. This second set of sales also maintained a weighted average price of $6.15 per share. The individual sale prices for these units were reported to fluctuate between $6.05 and $6.22.
In total across both days, Mr. Ye divested 22,220 shares of common stock through the reported sales activity. It is also important to note that preceding these sales, Mr. Ye had acquired 22,220 shares of GYRE THERAPEUTICS, INC. common stock by exercising fully vested stock options. These acquisitions were split across the two dates: 9,400 shares on May 20th and 12,820 shares on May 21st. The exercise price for these utilized options was $0.75 per share, leading to a total documented acquisition value of $16,665. These specific vested options are scheduled to expire on October 31, 2030.
Following the reported sales and acquisitions, Ye Weiguo currently holds a direct ownership stake of 700,000 shares of GYRE THERAPEUTICS, INC. common stock.
Contextualizing Insider Activity Against Company Fundamentals
These insider selling transactions occurred against a backdrop of current market pricing for GYRE stock. The equity is trading near its 52-week low of $5.97, reflecting declines of 7.5% over the past week and a more substantial decline of 46% across the last year.
From an analytical perspective, some data suggests that the stock currently appears slightly overvalued relative to its Fair Value estimate, according to InvestingPro analysis. However, the company faces specific financial challenges; as of Q1 2026, it reported a negative Earnings Per Share (EPS) of $0.08 in the last twelve months. Despite this profitability concern, GYRE maintains a robust balance sheet, evidenced by possessing more cash than debt and reporting a current ratio of 4.64.
Analysts have projected potential upside for the stock, suggesting it could reach between $18 and $20. This projection is based on anticipated growth, although analysts also forecast that sales are expected to decrease by 13% this year.
Strategic Growth Drivers and Regulatory Milestones
Beyond the stock transactions and financial metrics, GYRE Therapeutics has achieved several significant corporate milestones. The company has advanced its New Drug Application (NDA) for F351, which is designed to treat chronic hepatitis B-induced liver fibrosis. China’s National Medical Products Administration (NMPA) accepted this application, marking it as the second major product submission made by the firm to the regulatory body.
Furthermore, Gyre Therapeutics recently finalized an all-stock acquisition of Cullgen Inc., a clinical-stage biopharmaceutical company. This transaction was valued at approximately $300 million. Following the completion of this strategic acquisition, Dr. Ying Luo, formerly associated with Cullgen, assumed the roles of President and Chief Executive Officer of Gyre.
The regulatory progress surrounding F351 has been further emphasized by the NMPA granting it priority review status. This decision follows prior communication between the company and the regulatory body. In related developments supporting these corporate movements, H.C. Wainwright recently reiterated a Buy rating for GYRE Therapeutics, establishing a price target of $18.00, which is viewed in light of the recent acquisition announcement.
Collectively, these reported events paint a picture of a period marked by strategic growth and regulatory advancement for Gyre Therapeutics Inc., providing context to the movements observed in its stock valuation and insider holdings.